688235:SHA
BeOne Medicines AG
239,99 CN¥
arrow_downward
-1,64%(-4,01) 1G
14 ott, 15:00:02 GMT+8 · CNY
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per 688235 in corso…
Apertura
243,75 CN¥
Massimo
245,45 CN¥
Minimo
239,41 CN¥
Cap. mercato
289,03 Mld
Vol. medio
2,94 Mln
Volume
1,99 Mln
Rapporto P/E
85,71
Max 52 sett.
319,24 CN¥
Min 52 sett.
205,51 CN¥
Utili per azione
2,80 CN¥
N. di dipendenti
12K
Apertura
243,75 CN¥
Massimo
245,45 CN¥
Minimo
239,41 CN¥
Cap. mercato
289,03 Mld
Vol. medio
2,94 Mln
Volume
1,99 Mln
Rapporto P/E
85,71
Max 52 sett.
319,24 CN¥
Min 52 sett.
205,51 CN¥
Utili per azione
2,80 CN¥
N. di dipendenti
12K
Articoli giornalistici
Da fonti web e partner giornalistici
MarketBeat
·
1 ora fa
Sanders Morris Harris LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Simply Wall Street
·
6 ore fa
BeOne Medicines (ONC) Stock Trades Above Fair Value Following Its 103% Run
Profilo
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Informazioni su BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Dipendenti12K
Data di fondazione28 ott 2010
Sede-
Settore-
Sito webbeonemedicines.com